Day One Biopharmaceuticals Inc (NASDAQ: DAWN) on Tuesday, plunged -4.04% from the previous trading day, before settling in for the closing price of $7.93. Within the past 52 weeks, DAWN’s price has moved between $7.54 and $18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -39.15%. With a float of $74.28 million, this company’s outstanding shares have now reached $101.12 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.89%, operating margin of -165.65%, and the pretax margin is -67.36%.
Day One Biopharmaceuticals Inc (DAWN) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Day One Biopharmaceuticals Inc is 26.71%, while institutional ownership is 83.56%. The most recent insider transaction that took place on Feb 18 ’25, was worth 52,278. In this transaction COO, CFO AND SECRETARY of this company sold 4,370 shares at a rate of $11.96, taking the stock ownership to the 252,638 shares. Before that another transaction happened on Feb 18 ’25, when Company’s GENERAL COUNSEL sold 4,646 for $11.96, making the entire transaction worth $55,580. This insider now owns 39,602 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -39.15% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Day One Biopharmaceuticals Inc (DAWN) is currently performing well based on its current performance indicators. A quick ratio of 7.61 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.04, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Analysing the last 5-days average volume posted by the [Day One Biopharmaceuticals Inc, DAWN], we can find that recorded value of 0.89 million was lower than the volume posted last year of 1.18 million. As of the previous 9 days, the stock’s Stochastic %D was 22.26%. Additionally, its Average True Range was 0.50.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 1.03%, which indicates a significant decrease from 6.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.72% in the past 14 days, which was lower than the 58.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.41, while its 200-day Moving Average is $13.02. Now, the first resistance to watch is $7.86. This is followed by the second major resistance level at $8.10. The third major resistance level sits at $8.27. If the price goes on to break the first support level at $7.44, it is likely to go to the next support level at $7.27. Now, if the price goes above the second support level, the third support stands at $7.03.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
Market capitalization of the company is 771.31 million based on 101,355K outstanding shares. Right now, sales total 131,160 K and income totals -95,500 K. The company made 29,210 K in profit during its latest quarter, and -65,710 K in sales during its previous quarter.
